PV Bulletin

PRAC 3 September 2026: Starts safety review of injectable iron-containing medicines Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026 4 September 20

The Pharmacovigilance Risk Assessment Committee (PRAC) has commenced a safety review concerning injectable iron-containing medicines.

Primary source: View

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

PRAC has initiated a safety review of injectable iron-containing medicines, which may influence future regulatory actions and safety assessments.

Why it matters

This safety review could lead to new regulatory requirements or updates regarding the use and monitoring of injectable iron products, impacting patient safety and industry practices.

Action needed

Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Ongoing monitoring is required as new updates emerge from PRAC.

Evidence and confidence

Confidence: highSource updated: Sep 4, 2026

Full briefing

Practical implication

Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

In its recent meeting, PRAC started a safety review focused on injectable iron-containing medicines, following ongoing safety signals associated with these products. This action indicates potential regulatory implications for involved stakeholders.

What changed: PRAC has initiated a safety review of injectable iron-containing medicines, which may influence future regulatory actions and safety assessments.

Why it matters: This safety review could lead to new regulatory requirements or updates regarding the use and monitoring of injectable iron products, impacting patient safety and industry practices.

Practical implication: Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-09-04T00:00:00.000Z
  • Discovered by monitor: 2026-09-04T21:35:10.415Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu#Translated From French

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward